These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 11717181

  • 1. Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques.
    Baillie TA, Halpin RA, Matuszewski BK, Geer LA, Chavez-Eng CM, Dean D, Braun M, Doss G, Jones A, Marks T, Melillo D, Vyas KP.
    Drug Metab Dispos; 2001 Dec; 29(12):1614-28. PubMed ID: 11717181
    [Abstract] [Full Text] [Related]

  • 2. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, Melillo D, Doss G, Vyas KP.
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [Abstract] [Full Text] [Related]

  • 3. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.
    Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, Schwartz JI, Lasseter KC, Vyas KP, Baillie TA.
    Drug Metab Dispos; 2002 Jun; 30(6):684-93. PubMed ID: 12019196
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor.
    Davies NM, Teng XW, Skjodt NM.
    Clin Pharmacokinet; 2003 Jun; 42(6):545-56. PubMed ID: 12793839
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy.
    Prescilla RP, Frattarelli DA, Haritos D, Aranda JV, Edwards DJ.
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):661-4. PubMed ID: 15454838
    [Abstract] [Full Text] [Related]

  • 11. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of the solution oxidation of rofecoxib under alkaline conditions.
    Harmon PA, Biffar S, Pitzenberger SM, Reed RA.
    Pharm Res; 2005 Oct; 22(10):1716-26. PubMed ID: 16180130
    [Abstract] [Full Text] [Related]

  • 13. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
    Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K.
    J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
    [Abstract] [Full Text] [Related]

  • 14. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model.
    Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP.
    J Pharmacol Exp Ther; 2002 Jul; 302(1):369-73. PubMed ID: 12065739
    [Abstract] [Full Text] [Related]

  • 15. A rapid and sensitive high-performance liquid chromatography assay for rofecoxib in human serum.
    Aravind MK, Prescilla R, Ofenstein JP.
    J Chromatogr Sci; 2002 Jan; 40(1):26-8. PubMed ID: 11866383
    [Abstract] [Full Text] [Related]

  • 16. Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats.
    Oitate M, Hirota T, Koyama K, Inoue S, Kawai K, Ikeda T.
    Drug Metab Dispos; 2006 Aug; 34(8):1417-22. PubMed ID: 16679386
    [Abstract] [Full Text] [Related]

  • 17. Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.
    Gottesdiener K, Agrawal N, Porras A, Wong P, Rogers JD, Gertz BJ, Redfern JS, Marbury T.
    Am J Ther; 2003 Aug; 10(4):252-8. PubMed ID: 12845388
    [Abstract] [Full Text] [Related]

  • 18. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
    Lenz EM, D'Souza RA, Jordan AC, King CD, Smith SM, Phillips PJ, McCormick AD, Roberts DW.
    J Pharm Biomed Anal; 2007 Feb 19; 43(3):1065-77. PubMed ID: 17030109
    [Abstract] [Full Text] [Related]

  • 19. Intestinal uptake and biliary excretion of the isoflavone genistein in rats.
    Sfakianos J, Coward L, Kirk M, Barnes S.
    J Nutr; 1997 Jul 19; 127(7):1260-8. PubMed ID: 9202077
    [Abstract] [Full Text] [Related]

  • 20. Metabolism of 3-phenoxybenzoic acid and the enterohepatorenal disposition of its metabolites in the rat.
    Huckle KR, Chipman JK, Hutson DH, Millburn P.
    Drug Metab Dispos; 1981 Jul 19; 9(4):360-8. PubMed ID: 6114836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.